Verve Therapeutics

company

About

Verve Therapeutics is a genetic medicines company.

Details

Last Funding Type
Series A
Last Funding Money Raised
$63M
Industries
Biotechnology,Genetics,Life Science
Founded date
Jan 1, 2018
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
nasdaq:VERV
Legal Name
Verve Therapeutics, Inc.

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. It has been purpose-built for the task ahead, with a team of experts in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
4
$482.20M
Verve Therapeutics has raised a total of $482.20M in funding over 2 rounds. Their latest funding was raised on Jun 16, 2021 from a IPO round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jun 16, 2021 IPO $266.70M Detail
Jan 19, 2021 Series B $94M 12 Casdin Capital
Wellington Management
Detail
Jun 11, 2020 Series A $63M 6 GV Detail
May 7, 2019 Series A $58.50M 4 GV Detail

Investors

Number of Lead Investors
Number of Investors
4
14
Verve Therapeutics is funded by 14 investors. Casdin Capital and Wellington Management are the most recent investors.
Investor Name Lead Investor Funding Round
Casdin Capital Yes Series B
Wellington Management Yes Series B
Biomatics Capital Partners Series B
Cormorant Asset Management Series B
GV Series B
Janus Henderson Investors Series B
Logos Capital Series B
Novo Holdings Series B
RA Capital Management Series B
Redmile Group Series B

Employee Profiles

Number of Employee Profiles
9
Verve Therapeutics has 9 current employee profiles, including Executive Anthony Philippakis
Executive
Executive
Executive
Executive